CorMedix Q3 2024 Earnings Report $10.13 -0.69 (-6.38%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast CorMedix EPS ResultsActual EPS-$0.05Consensus EPS -$0.10Beat/MissBeat by +$0.05One Year Ago EPS-$0.17CorMedix Revenue ResultsActual Revenue$11.46 millionExpected Revenue$11.00 millionBeat/MissBeat by +$460.00 thousandYoY Revenue GrowthN/ACorMedix Announcement DetailsQuarterQ3 2024Date10/30/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptCRMD Earnings History CorMedix Earnings HeadlinesCormedix (NASDAQ:CRMD) Stock Quotes, Forecast and News SummaryFebruary 21 at 6:59 PM | benzinga.comCorMedix Inc. (NASDAQ:CRMD) Receives $15.67 Consensus Target Price from BrokeragesFebruary 15, 2025 | americanbankingnews.comElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.February 22, 2025 | True Market Insiders (Ad)CorMedix announces collaboration with WSI PBG for DefenCathJanuary 21, 2025 | markets.businessinsider.comD. Boral Capital Initiates Coverage of CorMedix (CRMD) with Buy RecommendationJanuary 14, 2025 | msn.comCorMedix initiated with a Buy at D. Boral CapitalJanuary 13, 2025 | markets.businessinsider.comSee More CorMedix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CorMedix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CorMedix and other key companies, straight to your email. Email Address About CorMedixCorMedix (NASDAQ:CRMD), a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.View CorMedix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
